ArticleBioscience reports2026
The interplay of the lncRNA AFAP1-AS1 and the soluble immune checkpoint proteins sPD-1/sPD-L1 in breast cancer: tumor-immune cross-talk.
Article in Bioscience reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Breast cancer (BC) remains a major health issue worldwide. Immuno-oncology has recently garnered much attention with unprecedented bench-to-bedside revolutions in cancer diagnosis and treatment. The PD-1/PD-L1 pathway is an adaptive mechanism in cancer immune escape that can be regulated epigenetically via long non-coding RNAs (lncRNAs). In the present study, we sought to investigate the potential clinical utility of the circulating lncRNA AFAP1-AS1 and soluble immune checkpoint proteins sPD-1 and sPD-L1 as liquid biopsy biomarkers in BC patients. Serum expression levels of AFAP1-AS1 were quantified via qRT‒PCR in a cohort comprising 90 BC patients (45 metastatic and 45 nonmetastatic) and 20 healthy controls, while serum sPD-1 and sPD-L1 levels were determined by ELISA. Computational bioinformatics approaches were employed to investigate molecular interactions among AFAP1-AS1, PD-1, and PD-L1 and to assess their functional roles in oncogenesis. Serum AFAP1-AS1, sPD-1, and sPD-L1 levels exhibited significant elevation in BC patients compared with controls, with further increases observed in metastatic versus non-metastatic cases. These biomarkers demonstrated significant association with positive lymph node involvement (P < 0.05). AFAP1-AS1 showed significant correlations with sPD-1 and sPD-L1, and their molecular interactions were demonstrated through in silico predictive analyses. ROC analysis revealed robust diagnostic and prognostic discriminatory potential. In conclusion, the present study underscores the clinical potential of the circulating lncRNA AFAP1-AS1, sPD-1, and sPD-L1 as promising non-invasive biomarkers in BC and may collectively reflect a coordinated immune evasion axis. The interplay between epigenetic modifications and immune checkpoint pathways represents a novel therapeutic target for enhancing antitumor immunity and halting metastasis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.